What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?

World Journal of Gastroenterology

Volumn 18, Issue 33, 2012, Pages 4604-4609

  Yan, Ying ^a   Mai, Li ^a   Zheng, Yu Bao ^a   Zhang, Shao Quan ^a   Xu, Wen Xiong ^a   Gao, Zhi Liang ^a   Ke, Wei Min ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Acute on chronic hepatitis B liver failure; Entecavir; Hepatitis B e antigen negativity; Model for end stage liver disease; Mortality

Indexed keywords

BILIRUBIN; CREATININE; ENTECAVIR; PROTHROMBIN; VIRUS DNA;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; SCORING SYSTEM; VIRUS LOAD;

EID: 84867738108     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i33.4604     Document Type: Article

References (25)

1. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217
2. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751
3. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020
4. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigennegative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-896
5. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588
6. Shu X, Xu QH, Chen N, Zhang K, Li G. [The clinic features and the short-term efficacy of entecavir treatment of the HBeAG negative acute-on-chronic hepatitis B liver failure]. Zhonghua Shiyan He Linchuang Bingduxue Zazhi 2008; 22: 481-483
7. Shu X, Xu QH, Chen N, Zhang K, Li G. [The clinic features and the short-term efficacy of entecavir treatment of the HBeAG negative acute-on-chronic hepatitis B liver failure]. Zhonghua Shiyan He Linchuang Bingduxue Zazhi 2008; 22: 481-483
8. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-270
9. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000; 7: 258-267
10. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Diseases and Artificial Liver Group. Diagnostic and treatment guidelines for liver failure. Zhonghua Chuan Ran Bing Zazhi 2006; 24: 422-425
11. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871
12. Chen LB, Cao H, Zhang YF, Shu X, Chen N, Zhang K, Li G, Xu QH. [Efficacy of antiviral treatment on patients with acute-on-chronic hepatitis B liver failure with low viral load]. Zhonghua Shiyan He Linchuang Bingduxue Zazhi 2010; 24: 364-366
13. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acuteon-chronic hepatitis B liver failure. J Gastroenterol Hepatol 2010; 25: 583-590
14. Yu JW, Sun LJ, Zhao YH, Li SC. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol 2008; 23: 1242-1249
15. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129
16. Sun QF, Ding JG, Xu DZ, Chen YP, Hong L, Ye ZY, Zheng MH, Fu RQ, Wu JG, Du QW, Chen W, Wang XF, Sheng JF. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat 2009; 16: 464-470
17. Yoshiba M. [Recent advances in the treatment of fulminant hepatitis B]. Nihon Rinsho 2004; 62 Suppl 8: 280-283
18. Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 2003; 12: 683-688
19. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, De-Hertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010
20. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. Two-year assessment of entecavir resistance in Lamivudinerefractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-911
21. Yao GB, Zhu M, Wang YM, Xu DZ, Tan DM, Chen CW, Hou JL. A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B. Zhanghua Neike Zazhi 2006; 45: 891-895
22. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656-1665
23. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-962
24. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
25. Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother 2007; 60: 201-205